Armata Pharmaceuticals, Inc. (ARMP) - 10-Q Summary
Business Context and Reporting Period
Company: Armata Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: A late clinical-stage biotechnology company developing bacteriophage therapeutics for antibiotic-resistant bacterial infections. The company operates as a single segment focused on two primary candidates: AP-PA02 (Pseudomonas aeruginosa) and AP-SA02 (Staphylococcus aureus).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Grant and Award Revenue | $2,510 | $3,299 |
| Total Operating Expenses | $12,822 | $22,396 |
| Operating Loss | $(10,312) | $(19,097) |
| Net Income (Loss) | $74,141 | $(41,205) |
| Cash and Cash Equivalents (Balance Sheet) | $23,952 (as of June 30, 2026) | |
| Total Debt (Current + Non-Current) | $283,508 (Convertible Loan: $163,904; Term Debt: $119,604) | |
| Accumulated Deficit | $(542,739) |
Note: The Net Income for the three months ended June 30, 2026, is driven primarily by a $91.0 million non-cash gain from the change in fair value of the Convertible Loan. The six-month period reflects a net loss due to a $10.0 million loss on the same item.
Material Changes vs. Prior Period
- Revenue: Grant and award revenue increased 15.7% quarter-over-quarter (QoQ) and 24.0% year-over-year (YoY) for the six-month period, driven by the MTEC award.
- Operating Expenses: Total operating expenses increased 42.3% QoQ and 26.6% YoY (six months).
- R&D: Increased 18.6% QoQ due to higher personnel costs (stock-based compensation) and manufacturing materials, despite a 94.6% decrease in clinical trial costs.
- G&A: Increased 99.9% QoQ, primarily due to stock-based compensation, legal fees, and incentive compensation.
- Debt Structure: Significant refinancing activity occurred in early 2026. The company entered into a $25.0 million term loan in May 2026 and amended existing credit agreements (2023, 2024, 2025) to extend maturities to June 2027. These amendments were accounted for as a Troubled Debt Restructuring (TDR).
- Convertible Loan Fair Value: The fair value of the Convertible Loan shifted from a loss of $5.8 million in Q2 2025 to a gain of $91.0 million in Q2 2026, reflecting changes in valuation methodology and stock price fluctuations.
Guidance, Outlook, and Risks
- Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Cash of $24.0 million is insufficient to fund operations for the next 12 months. Additional capital is required via equity, debt, or collaborations.
- Clinical Progress:
- AP-SA02: Received Qualified Infectious Disease Product (QIDP) and Fast Track Designations from the FDA. The Phase 3 superiority study protocol was submitted to the FDA, with initiation anticipated in the second half of 2026.
- AP-PA02: Completed Phase 2 studies in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis. Future Phase 3 development is contingent on securing funding.
- Financing: The company maintains an At-The-Market (ATM) offering program, raising $2.4 million in the first half of 2026. Recent debt financings include $25.0 million (May 2026) and $15.0 million (August 2025) term loans at 14.0% interest.
- Risks: Key risks include the inability to raise additional capital, failure of clinical trials, regulatory delays, and the high cost of debt servicing (interest expense increased 74.2% QoQ).
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for the next capital raise given the explicit "substantial doubt" regarding going concern status.
- Debt Covenants: Review the specific financial covenants and mandatory prepayment triggers in the amended credit agreements (2023, 2024, 2025, 2026) to assess default risk.
- Convertible Loan Valuation: Scrutinize the $91.0 million non-cash gain; understand that this does not represent cash flow and is subject to volatility based on stock price.
- Phase 3 Funding: Confirm the specific funding sources identified for the AP-SA02 Phase 3 trial, which is expected to start in H2 2026.
- Stock-Based Compensation: Note the significant increase in stock-based compensation ($4.5 million for six months) and its impact on future cash burn if equity issuance is restricted.